Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) held its first R&D Day on Wednesday, and the message was clear: the generics giant wants to be known for something else. Specifically, it's targeting $6 billion to $7 billion in innovative medicine revenue by 2030.
President and CEO Richard Francis laid out a strategy that aims to launch one novel treatment annually over the next five years. The pitch leans on a refined research and development model built around data-driven capital allocation and accelerated clinical timelines.
That late-stage pipeline currently holds a combined peak sales potential exceeding $10 billion, pending regulatory approvals. Teva recently accelerated development schedules for WELTRUZA, moving directly from Phase 1 to Phase 3, and advanced ecopipam to FDA priority review.
Advancing Clinical Candidates
Teva also highlighted multiple early-stage pipeline assets meant to sustain growth beyond 2030.
The Anti-IL-15 program for celiac disease achieved its primary Phase 2a endpoint, with a Phase 2b trial planned for the second half of 2027. Meanwhile, the TEV-'408 asset is moving seamlessly into Phase 2/3 trials for vitiligo and will undergo evaluation for alopecia.
The company is also progressing its anti-PD-1/IL-2 asset, ATTENUKINE, in Phase 1 trials for advanced cancer, while utilizing in-house capabilities to develop precision antibodies for asthma and inflammatory bowel disease.
Execution And Financial Stabilization
Since initiating its Pivot to Growth strategy in 2023, Teva successfully doubled its innovative medicine revenue. Key products including AUSTEDO, AJOVY, and UZEDY are projected to grow roughly 125% by the close of 2026.
The company recently launched WELTRUZA, pushing innovative medicines to over 20% of total revenue. Simultaneously, the generics segment stabilized, biosimilar revenue is forecast to double between 2024 and 2026, and the company generated over $6 billion in free cash flow from 2023 to 2025.
Robust 2030 Financial Outlook
Regaining an investment-grade credit rating in 2026 provided Teva with a solid financial foundation to fund pipeline expansions and commercial launches.
Looking toward 2030, the pharmaceutical company targets innovative gross margins above 75%, mid-single-digit total revenue growth, and more than $3.5 billion in annual free cash flow. Additionally, management established a clear path to lower its net debt leverage to 2.0x by late 2027.
TEVA Price Action: Teva Pharmaceutical Indus shares were up 0.47% at $42.60 at the time of publication on Wednesday. The stock is trading near its 52-week high of $43.34, according to market data.
